Results per Page:
When it comes to cancer trials, what’s the (end)point?
New endpoint in multiple myeloma could mean faster drug approvals. Are more endpoint tweaks on the way?
The response is what counts
From the Othus Group, Public Health Sciences Division
Othus joins Hutchinson Center biostatisticians
Harvard graduate applies analytic skills to clinical trials